"10.1371_journal.pone.0066886","plos one","2013-06-24T00:00:00Z","Joanne Van Der Velden; Grace Sum; Donna Barker; Emmanuel Koumoundouros; Garry Barcham; Heike Wulff; Neil Castle; Peter Bradding; Kenneth Snibson","Faculty of Veterinary Science, The University of Melbourne, Parkville, Victoria, Australia; Lung Health Research Centre, Department of Pharmacology, University of Melbourne, Parkville, Victoria, Australia; Department of Electrical and Electronic Engineering, University of Melbourne, Parkville, Victoria, Australia; Department of Pharmacology, University of California Davis, Davis, California, United States of America; Icagen Inc., Durham, North Carolina, United States of America; Department of Infection, Immunity and Inflammation, Institute for Lung Health, University of Leicester, Leicester, United Kingdom","Conceived and designed the experiments: JVDV EK HW NC PB KS. Performed the experiments: JVDV GS DB GB EK KS. Analyzed the data: JVDV EK KS. Contributed reagents/materials/analysis tools: NC. Wrote the paper: JVDV NC HW PB KS.","Heike Wulff consulted for NeuroSearch A/S on KCa3.1 (2009–2011). Peter Bradding has acted as an advisor to Icagen (2007–2010). At the time of the experiments Neil Castle was an employee of Icagen, the company who identified and developed Senicapoc. Ken Snibson is a shareholder of Allergenix Pty Ltd, who holds a patent on the allergic HDM sheep model for asthma in Australia. This does not alter the authors adherence to all the PLOS ONE policies on sharing data and materials.","2013","06","Joanne Van Der Velden","JVDV",9,TRUE,6,6,3,5,TRUE,TRUE,FALSE,0,NA,FALSE
